Each 1 mg/dL increment in serum phosphorus was associated with a 1.74-fold increased risk of incident heart failure (95% CI 1.17-2.59) over a mean follow-up of 17.4 years.
Cohort (n=3,300)
Does higher serum phosphorus increase the risk of incident heart failure and adverse left ventricular remodeling in a community-based population free of baseline cardiovascular and kidney disease?
Higher serum phosphorus levels are independently associated with adverse left ventricular remodeling and a significantly increased risk of incident heart failure in a healthy community cohort.
Hazard Ratio: 1.74 (95% CI 1.17–2.59)
AIMS: To evaluate the association of serum phosphorus with cardiac structure/function and incident heart failure. METHODS AND RESULTS: We related serum phosphorus to echocardiographic left ventricular (LV) measurements cross-sectionally, and to incident heart failure prospectively in 3300 participants (mean age 44 years, 51% women) free of heart failure, myocardial infarction, and chronic kidney disease (estimated glomerular filtration rate eGFR90 mL/min/1.73 m(2), no proteinuria and serum phosphorus <4.5 mg/dL, the association of serum phosphorus with heart failure remained robust. CONCLUSION: In our community-based sample, higher serum phosphorus was associated with greater LV mass cross-sectionally, and with an increased risk of heart failure prospectively.
Dhingra et al. (Sat,) conducted a cohort in Community-dwelling adults (n=3,300). Serum phosphorus vs. Lower serum phosphorus levels was evaluated on incident heart failure (HR 1.74, 95% CI 1.17-2.59). Each 1 mg/dL increment in serum phosphorus was associated with a 1.74-fold increased risk of incident heart failure (95% CI 1.17-2.59) over a mean follow-up of 17.4 years.